Search

Displaying results 3551 - 3560 of 3874 in total
  1. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots.

  2. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible...

    Synonyms: (5α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
  3. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  4. Drug

    Elvucitabine

    go.drugbank.com/drugs/DB06236
    Investigational

  5. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication. The key role of Mp...

  6. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional im...

  7. Drug

    Cinchophen

    go.drugbank.com/drugs/DB13551
    Experimental

    Categories: Preparations With No Effect on Uric Acid Metabolism
  8. Drug

    Pyrazinamide

    go.drugbank.com/drugs/DB00339
    ApprovedInvestigational

    A pyrazine that is used therapeutically as an antitubercular agent.

    Mixtures: AKURIT-Z KID DISPERSIBLE TABLETS
  9. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    If approved for use, it will be the first available agent for the treatment of NASH.

  10. Drug

    Leronlimab

    go.drugbank.com/drugs/DB05941
    Investigational

    Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.